Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial

Autor: Albert C Ludolph, Joachim Schuster, Johannes Dorst, Luc Dupuis, Jens Dreyhaupt, Jochen H Weishaupt, Jan Kassubek, Ulrike Weiland, Susanne Petri, Thomas Meyer, Julian Grosskreutz, Berthold Schrank, Matthias Boentert, Alexander Emmer, Andreas Hermann, Daniel Zeller, Johannes Prudlo, Andrea S Winkler, Torsten Grehl, Michael T Heneka, Siw Wollebæk Johannesen, Bettina Göricke, Andreas Funke, Dagmar Kettemann, Robert Meyer, Kai Gruhn, Peter Schwenkreis, Philipp Stude, Delia Kurzwelly, Alexander Storch, Nicole Richter, Tobias Frank, Katharina Hein, Frank Hanisch, Dagmar Hanke, Torsten Kraya, Andreas Posa, Martina Romanakova, Susanne Schilling, Susanne Abdulla, Sebastian Böselt, Claas Janssen, Imken Lange, Xenia Kobeleva, Sonja Körner, Katja Kollewe, Alma Osmanovic, Nicole Scharn, Klaus J Rath, Christiane Dahms, Anne Gunkel, Bianka Heiling, Thomas Ringer, Uta Smesny, Sarah Baumeister, Achim Berthele, Sarah Bublitz, Esra Akova-Öztürk, Bianca Stubbe-Dräger, Alexandra Rahmann, Charlotte Young, Peter Young, Dobri Baldaranov, Ulrich Bogdahn, Andrei Khomenko, Wilhelm Schulte-Mattler, Christina Stadler, Susanne Husung, Simone Tesar, Nigar Dargah-Zaden, Christina Last, Eva Langer, Ann-Sophie Lauenstein, Eckard Lensch, Carolyn Mc Farlane, Heike Fischer-Brasse, Klara Orbán, Bertold Schrank, Sonja Schürger, Stephan Klebe, Peter Kraft, Thomas Musacchio, Carola Seiler

Publikováno v: The Lancet Neurology
The Lancet Neurology, Elsevier, 2018, 17 (8), pp.681-688. ⟨10.1016/S1474-4422(18)30176-5⟩
The Lancet Neurology, 2018, 17 (8), pp.681-688. ⟨10.1016/S1474-4422(18)30176-5⟩

International audience; Background: Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral scleros

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b70e9f6bbf70e7d2a063a95b23e7ffaa
https://doi.org/10.1016/s1474-4422(18)30176-5

Analysis of the therapeutic potential of different administration routes and frequencies of human mesenchymal stromal cells in the SOD1 G93A mouse model of amyotrophic lateral sclerosis

Autor: Ulrike Köhl, Anastasia Sarikidi, Alma Osmanovic, Stephan Klöß, Franziska Bursch, Ekaterini Kefalakes, Susanne Petri, Nadine Thau-Habermann, Sebastian Böselt, Klaus Jan Rath

Publikováno v: Journal of Tissue Engineering and Regenerative Medicine. 13:649-663

Cellular therapy represents a novel option for the treatment of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS). Its major aim is the generation of a protective environment for degenerating motor neurons. Mesenchymal stromal c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a9c55a6f1848bbbdf10ce0f004afc47
https://doi.org/10.1002/term.2846

Lower motor neuron involvement in ALS assessed by motor unit number index (MUNIX): Long-term changes and reproducibility

Autor: Susanne Petri, Davood Fathi, Reinhard Dengler, Sebastian Böselt, Bahram Mohammadi, Katja Kollewe

Publikováno v: Clinical Neurophysiology. 127:1984-1988

Motor unit number estimation (MUNE) techniques such as motor unit number index (MUNIX) have been used to quantify lower motor neuron loss and disease progression in amyotrophic lateral sclerosis (ALS). We investigated the consistency of reproducibili

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4912075f95c095b8b953eb44626a71d
https://doi.org/10.1016/j.clinph.2015.12.023

Analysis of the therapeutic potential of different administration routes and frequencies of human mesenchymal stromal cells in the SOD1

Autor: Franziska, Bursch, Klaus Jan, Rath, Anastasia, Sarikidi, Sebastian, Böselt, Ekaterini, Kefalakes, Alma, Osmanovic, Nadine, Thau-Habermann, Stephan, Klöß, Ulrike, Köhl, Susanne, Petri

Publikováno v: Journal of tissue engineering and regenerative medicine. 13(4)

Cellular therapy represents a novel option for the treatment of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS). Its major aim is the generation of a protective environment for degenerating motor neurons. Mesenchymal stromal c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::41afce62f6a8be4b057e665953c21cb6
https://pubmed.ncbi.nlm.nih.gov/30811816

A Chemical Chaperone-Based Drug Candidate is Effective in a Mouse Model of Amyotrophic Lateral Sclerosis (ALS)

Autor: Olga Viskind, Arie Gruzman, Hanoch Senderowitz, Susanne Petri, Daniel Offen, Omer Green, Inchan Kwon, Yael Barhum, Simpson Gregoire, Ilana Zaks, Tom Shani, Hugo E. Gottlieb, Tali Ben-Zur, Adrian Israelson, Sebastian Böselt, Tamar Getter, Moran Shubely

Publikováno v: ChemMedChem. 10:850-861

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the selective death of motor neurons and skeletal muscle atrophy. The majority of ALS cases are acquired spontaneously, with inherited disease accounting for on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3991251fba6560814288c44bea240a49
https://doi.org/10.1002/cmdc.201500045